Eli Lilly and Company (LLY · NYSE)
LLY · MARKET VIEW
Market view · as of Jun 22, 2026
Revenue (TTM)
$72.25B
+55.5% YoY
Gross margin
82.8%
EPS (latest q)
$8.55
vs $6.79 est · beat
52-wk position
88.4%
-5.4% vs 52w high · +7.8% 1mo
Price (last ~year)
Eli Lilly and Company (LLY) reported first-quarter 2026 revenue of $19.80 billion and net income of $7.40 billion, representing year-over-year growth of 55.5% and 169.9%, respectively. The company has exceeded earnings estimates for four consecutive quarters, supported by an 82.8% gross margin and a 49.4% operating margin. With a market capitalization of $979.64 billion, the stock is currently priced at $1,098.57, reflecting a 21.9% increase over the last three months.
Valuation
- Market cap
- $979.64B
- P/E
- 39.07
- PEG
- 1.473
- P/B
- 31.4
- P/S
- 13.56
- EV/EBITDA
- 28.1
- Beta
- 0.517
- Analyst target
- $1218.72
Quality & returns
- Gross margin
- 82.8%
- Operating margin
- 49.4%
- Profit margin
- 35.0%
- ROE
- 107.5%
- ROA
- 20.7%
Price movement
- Last
- $1098.57
- 1-month
- +7.8%
- 3-month
- +21.9%
- RSI (14)
- 49
- vs SMA200
- +14.0%
- 52-wk position
- 88.4% -5.4% vs high
Quarterly trajectory
Revenue by quarter (oldest → newest)
| Quarter | Revenue | Op income | Net income | EBITDA |
|---|---|---|---|---|
| 2026-03-31 | $19.80B | $8.85B | $7.40B | $9.69B |
| 2025-12-31 | $19.29B | $8.78B | $6.64B | $8.39B |
| 2025-09-30 | $17.60B | $8.39B | $5.58B | $7.88B |
| 2025-06-30 | $15.56B | $7.13B | $5.66B | $7.50B |
Recent news
- Somewhat-Bullish 39,048 Shares in CVS Health Corporation $CVS Acquired by Stance Capital LLC · 2026-06-21
- Somewhat-Bullish 6,621 Shares in Republic Services, Inc. $RSG Purchased by Stance Capital LLC · 2026-06-21
- Somewhat-Bullish Charles River Laboratories International (CRL) Stock Could Be 41% Undervalued After Lilly Tie Up And Upgrade · 2026-06-21
- Bullish Charles River Laboratories International (CRL) Stock Could Be 41% Undervalued After Lilly Tie Up And Upgrade · 2026-06-21
- Somewhat-Bullish LifeVantage Corp (LFVN) Earnings Forecast: Future EPS & Revenue Growth Estimates · 2026-06-20
- Somewhat-Bullish Pfizer (PFE) Stock Could Be 10% Undervalued After CFO Exit Raises Execution Questions · 2026-06-20
Sources this view read
- fundamentals Company overview & valuation (Alpha Vantage OVERVIEW)
- filing Quarterly financial statements (Alpha Vantage INCOME/BALANCE/CASH)
- earnings Reported earnings history (Alpha Vantage EARNINGS)
- prices Adjusted daily prices (Alpha Vantage TIME_SERIES_DAILY_ADJUSTED)